Avid Bioservices, Inc. (NASDAQ:CDMO), a renowned biologics contract development and manufacturing organization (CDMO), revealed the successful pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the 2029 Notes), as announced on March 6, 2024. In an effort to raise capital, the company entered into private placement purchase agreements with various qualified institutional buyers, in accordance with Rule 144A under the Securities Act of 1933, as amended. The offering, subject to customary closing conditions, is expected to conclude on March 12, 2024.
This strategic move demonstrates Avid Bioservices’ commitment to continue expanding and growing its capabilities within the biologics sector. By securing $160 million through the issuance of Convertible Senior Notes, the company aims to strengthen its financial position and support its ongoing research and development efforts.
These 2029 Notes will be convertible into shares of Avid Bioservices’ common stock at the option of the noteholders, or even at the company’s option under certain circumstances. The specific terms and conditions of the conversion will be detailed in the related offering memorandum.
Avid Bioservices firmly believes that this private placement of Convertible Notes will bring remarkable opportunities for further growth and development. The funds raised will allow the company to pursue new initiatives, develop advanced technologies, and enhance its manufacturing capabilities. Moreover, by attracting the interest of qualified institutional buyers, Avid Bioservices has garnered significant trust and credibility within the industry.
The biologics contract development and manufacturing market is witnessing an upward trend, driven by increasing demand for innovative therapies and personalized medicines. This favorable market climate positions Avid Bioservices well to capitalize on the growing need for specialized biologics manufacturing services.
Avid Bioservices’ announcement marks a significant milestone as the company embarks on a new chapter of growth and expansion. By successfully raising capital through the private placement of Convertible Notes, Avid Bioservices is poised to scale new heights in the biologics industry.
Comments